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Antibody-Dependent Enhancement 
of Dengue Virus Infection in 
Primary Human Macrophages; 
Balancing Higher Fusion against 
Antiviral Responses
Jacky Flipse1, Mayra A. Diosa-Toro1,2, Tabitha E. Hoornweg1, Denise P. I. van de Pol1, 
Silvio Urcuqui-Inchima2 & Jolanda M. Smit1
The dogma is that the human immune system protects us against pathogens. Yet, several viruses, 
like dengue virus, antagonize the hosts’ antibodies to enhance their viral load and disease severity; a 
phenomenon called antibody-dependent enhancement of infection. This study offers novel insights 
in the molecular mechanism of antibody-mediated enhancement (ADE) of dengue virus infection in 
primary human macrophages. No differences were observed in the number of bound and internalized 
DENV particles following infection in the absence and presence of enhancing concentrations of 
antibodies. Yet, we did find an increase in membrane fusion activity during ADE of DENV infection. The 
higher fusion activity is coupled to a low antiviral response early in infection and subsequently a higher 
infection efficiency. Apparently, subtle enhancements early in the viral life cycle cascades into strong 
effects on infection, virus production and immune response. Importantly, and in contrast to other 
studies, the antibody-opsonized virus particles do not trigger immune suppression and remain sensitive 
to interferon. Additionally, this study gives insight in how human macrophages interact and respond to 
viral infections and the tight regulation thereof under various conditions of infection.
Through the evolutionary process, viruses have acquired many mechanisms to hijack the host cell machinery and 
to suppress antiviral responses within infected cells. More intriguingly, viruses have found ways to antagonize 
the host immune system by using the hosts’ antibodies to enhance infection and disease: a phenomenon called 
antibody-dependent enhancement (ADE)1,2. In vitro, ADE has been shown for influenza A virus3, Coxsackievirus 
B4, respiratory syncytial virus5, Ebola virus6, human immunodeficiency virus (HIV)7, and many other viruses8. 
In vivo ADE has been linked with the severity of HIV7 and dengue virus (DENV) infection9,10.
DENV infection is the most prevalent arthropod-borne viral infection worldwide with approximately 390 
million infections and 96 million symptomatic cases in 201011. Four serotypes of DENV exist (DENV1–4) and 
symptomatic infection with any DENV serotype leads to mild dengue fever or to the life-threatening dengue 
haemorrhagic fever and dengue shock syndrome9.
The question why some patients develop dengue fever, and others dengue haemorrhagic fever or dengue shock 
syndrome is continuously under investigation and debate. Epidemiologic research showed that severe dengue 
disease is strongly associated with primary infection of infants with waning maternal anti-dengue immunity10,12, 
and with secondary, heterotypic dengue infection13–16. Patients with severe dengue disease often present high viral 
loads early in infection17–19. In line with this, heterotypic sub-neutralizing antibodies, or waning concentrations of 
homotypic antibodies have been found to enhance DENV infectivity in vitro and in vivo12,20,21.
So far, little is known about how antibodies enhance DENV infection and disease20,22. Previously, antibodies 
were found to increase the number of infected cells and, subsequently, facilitate higher virus production once the 
concentration of the antibody falls below the neutralization threshold23–26. Furthermore, it has been suggested 
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that DENV immune-complexes would boost virus production per infected cell (burst size) by suppressing intra-
cellular antiviral responses22,27–29. The latter is also called intrinsic ADE to stress putative involvement of an intra-
cellular mechanism. Consequently, enhancement of the infected cell mass is named extrinsic ADE.
DENV replicates in macrophages, monocytes, and dendritic cells in vitro24,30,31 and in vivo32. During second-
ary infection, i.e. in the presence of antibodies, monocytes and macrophages actively support ADE, whereas 
immature dendritic cells do not23,24,33. Indeed, studies with primary macrophages and monocytes found that ADE 
can enhance DENV burst sizes in the order of 5.3- to 7.2-fold23–25. Here, we focused on one cell type, i.e. primary 
human macrophages, and attempted to discern the mechanism of enhanced DENV infection within this cell type.
We discovered that, in primary human macrophages, antibody-mediated cell entry of DENV enhances the 
fusion potential of the virus. No enhanced binding and entry was seen. Also, we observed that ADE does not 
induce an increased antiviral response early in infection. We propose that the increase in membrane fusion activ-
ity initiates an aggravating cascade leading to the typical enhancement of (i) infection, (ii) burst size, and (iii) 
disproportionally stronger anti-inflammatory responses. Importantly, no antibody-mediated immunosuppressive 
signalling was detected in primary human macrophages. Our data suggests that DENV antagonizes the host anti-
body as a vehicle to enhance its fusion efficiency within macrophages and consequently enhance disease severity.
Methods
Antibodies. Human monoclonal antibodies (#753 C6 and #751 A2) against the DENV2 E protein were a kind 
gift of J. Mongkolsapaya and G. Screaton (Imperial College, UK). Human IgG Fc-fragments were used as control 
(Jackson immunoResearch, USA). Antibodies for the phenotyping of the macrophages, and corresponding iso-
types, were obtained through an unrestricted grant (Immunotools, DE).
Cell lines. Baby Hamster Kidney cells (BHK-15), gift of Richard Kuhn, Purdue University, were propagated 
in Dulbecco’s minimal essential medium (DMEM) (Gibco, NL) supplemented with 10% Fetal Bovine Serum 
(FBS) (Lonza, USA), 100 U/mL penicillin and 100 mg/mL streptomycin (PAA, Switzerland), 0.75 g/L sodium 
bicarbonate (Gibco). The green monkey-derived Vero WHO cell line (WHO RCB 10–87), gift of James Brien, was 
cultured as described for the BHK-15, yet at 5% FBS. P338D1 cells (ATCC, #CCL-46) were cultured as described 
for BHK-15, with addition of 1mM sodium pyruvate (Gibco).
Macrophages. Buffy coats were obtained from anonymous donors with informed consent from Sanquin 
blood bank (Groningen, the Netherlands), in line with the declaration of Helsinki. The flavivirus-immune status 
of the 23 blood donors that we used is unknown but it is unlikely that a major proportion is flavivirus-positive. 
PBMCs were isolated by Ficoll-Paque (GE Healthcare, Belgium) gradient, and stored in 90% FBS, 10% DMSO on 
liquid nitrogen till use. Monocytes were isolated from total PBMCs, as described previously31, and differentiated 
into macrophages by culturing in 12-wells plates for 6 days at 37 °C, 5% CO2 in RPMI with HEPES (Gibco), sup-
plemented with 20% FBS and 100 ng/mL recombinant human M-CSF (Prospec-Tany, Israel). On alternate days, 
75% of the medium was replaced with medium and the full amount of M-CSF.
Virus stocks. Dengue virus serotype 2, strain 16681 (DENV2) was propagated on C6/36 cell line, as described 
previously34,35. The specific infectivity of the virus stock was 79 genomes per PFU. Purification was performed as 
described by Ayala et al.35. Vesicular Stomatitis Virus, Indiana serotype, strain San Juan A (VSV) was propagated 
on Vero WHO cells. Vero WHO cells were infected at MOI 0.1 in cell culture medium with 2% FBS. After 24 h, 
the culture medium was harvested, clarified, and mixed with HEPES (PAA, Switzerland) to 10 mM final concen-
tration. All virus samples were aliquoted and snap frozen in liquid nitrogen prior to storage at − 80 °C.
Infectious virus titers were determined by plaque assay. DENV2 titers were determined on BHK-15 cells. 
VSV was titrated on Vero WHO cells. The limit of detection is 40 PFU/mL. In brief, for both plaque assays, cells 
were seeded the day before infection (1 ∙ 105 per well in 24-wells plates). Serial dilutions of virus supernatant were 
added to the cells followed by 2 h incubation at 37 °C prior to placing an overlay of 1% seaplaque agarose (Lonza, 
Switzerland) in MEM (Gibco). Cells were fixed at 1 (VSV) or 6 days post infection (DENV2). Plaques were visu-
alized with crystal violet (TCS biosciences, UK).
The number of genome-containing particles was determined as previously described34 with minor 
modifications.
Virus labelling. DENV2 was labelled with DiD (Molecular Probes, USA) as described before35. Virus label-
ling with PKH67 (Sigma, USA) was performed based on Balogh et al.36. Briefly, 1.5 ∙ 108 GCPs of tartrate-purified 
DENV2 was diluted in PBS to 100 μ L and mixed with 1 μ L PKH67 dye in 99 μ L Diluent C (Sigma, USA). At 30 
seconds post addition, 300 μ L of pure FBS was added to stop the labelling. PKH67-labelled virus was used directly 
after labelling.
Infection of macrophages. Prior to infection, two wells were trypsinized using 10xTrypsin/EDTA (Gibco) 
and counted to determine the required amount of virus for each multiplicity-of-infection (MOI). To standardize 
the opsonisation in ADE experiments, a fixed ratio of antibodies to virus particles was used; per 1 · 105 PFU of 
DENV2, we added 3 ng of antibody in 75 μ L total volume. Thereafter, viruses and antibodies were incubated for 
1 h at 37 °C prior to addition to the cells. Cells were washed with warm RPMI and infected at the indicated MOI in 
200 μ L per well. At 2 hpi, cells were washed to remove extracellular virus and incubation was continued in culture 
medium (RPMI, 20% FBS, and 10 ng/mL M-CSF). For virus titrations, culture samples were snap-frozen in liquid 
nitrogen and stored at − 80 °C until analysis.
For binding and entry studies, the virus was added to the cells and left to incubate for the designated time peri-
ods. At the end, the inoculum was removed, and the cells were lysed in AVL buffer (Qiagen) to determine the total 
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number of particles by qRT-PCR. For the entry studies, cells were gently rocked for 2 min with high-salt-high-pH 
shaving buffer (1M NaCl, pH 9.5) prior to lysis in AVL buffer.
Flow cytometric of DENV-infected macrophages was performed using 4G2 antibody (Millipore, UK) and 
donkey anti-mouse IgG-coupled to AF647 (Molecular Probes). Hereto, trypsinized macrophages were fixed with 
4% paraformaldehyde in PBS and permeabilized with saponin (Sigma, USA). Flow cytometry was performed on 
a FACScalibur (BD Biosciences) and analysed using FlowJo 7.6.2 or Kaluza 1.1.
Viral protein translation was determined using the mean fluorescence intensity of infected cells, Hereto, 
infected cells were gated in Kaluza and the mean fluorescence intensity of AF647 was determined for each sam-
ple. Values were expressed as percentage of the maximal fluorescence intensity observed within the donor/exper-
iment. Extracellular virus particles did not contribute to the fluorescence signal.
Macrophage IFNα β R signalling was blocked using the mouse anti-human IFNα β R2 (Millipore) by 
pre-incubating the cells for 2 h with 0.5 μ g/well of antibody. Then, cells were infected and cultured as usual, in the 
presence of the antibody (1 μ g/mL). Infection was scored at 26 hpi and 48 hpi by qRT-PCR. Specificity of IFNα β R 
blocking was confirmed by quantifying surface expression of CD14 and MHC class I by flow cytometry.
For the interferon-alpha add-on experiments; macrophages were infected as described above. At the desig-
nated time points, 1 unit/mL of recombinant interferon α 2a (Prospec-Tany, 2.7 · 108 IU/mg) was added to the cul-
ture and the concentration was maintained throughout the remainder of the experiment. At 26 hpi, virus particle 
production was determined by qRT-PCR.
Fusion assay on primary human macrophages. Isolation and culture of macrophages was initiated as 
described above. On the second day of culture, the cells were gently dissociated by incubation at 4 °C for 15 min-
utes followed by gentle pipetting. Subsequently, cells were reseeded at 2 ∙ 105 per quadrant in 500 μ L in CELLview 
dishes (Greiner Bio-One, DE). Subsequent culture and infection was done as above. At 30 min post-infection, 
extracellular virus was removed by gentle washing the cells with shaving buffer followed by fixation with 4% 
PFA-PBS. Fusion activity was determined as described before35. Briefly, wide-field microscopy analysis was done 
by taking 15–30 random snapshots using both differential interference contrast and DiD-channels in a Leica 
Biosystems 6000B instrument with a 635-nm helium-neon laser. Acquired images were analysed with ImageJ 
using an in house macro35 measuring the total fluorescent signal per field of view with the “Particle analyzer” 
plugin of ImageJ. Fluorescence intensity was normalized relative to MOI 1. The fraction of fusion-positive cells, 
with at least one bright fluorescent spot, was blindly scored.
Antiviral bio-assay. The antiviral response in culture supernatants was determined using VSV and Vero 
WHO cells as described before25. Briefly, Vero WHO cells were seeded in 12-wells plates at 2 ∙ 105 per mL per 
well. After adherence for 8 h, cells were incubated for 12 h with UV-inactivated supernatant, followed by infection 
with VSV at an MOI of 0.1 in 100 μ L. At 1 hpi, inoculum was removed and cells were washed. Incubation was 
continued in fresh UV-inactivated supernatant. At 6 hpi, medium was collected and VSV titers were determined 
by plaque assay. Experimental results are reported as percentage of mock-medium. Recombinant human inter-
feron–alpha (Prospec-Tany) served as positive control.
Microarray. Macrophages were infected at MOI 1, MOI 1-ADE and MOI 1-IgG. Matched infection controls 
represent conditions resulting in similar fractions of infected cells; i.e. infection at MOI 5 or MOI 2½ (3 and 1 
donor at 2 hpi, 2 and 1 donor at 24 hpi, respectively). Cellular RNA was extracted with RNeasy Plus (Qiagen) 
as per manufacturer’s instructions. RNA was processed in house and randomly annealed to Human HT-12 V3 
BeadChip array (Illumina, USA), as per manufacturers’ protocol. Data was converted using GeneSpring (Agilent 
Technologies, USA). Probe values were normalized against the total signal intensity of the sample and subse-
quently, the fold change of the probes were expressed relative to mock condition of the same donor. For each time 
point, the donors were pooled and averaged. Probes with an absolute, average fold-change of ≥ 1.5 relative to the 
mock were considered differentially regulated. Probes were manually curated to single gene level, independent of 
the potential isoforms, and Venn diagrams were drawn based on overlaps between infection conditions. All data 
is been freely available through ArrayExpress ID: E-MTAB-3138.
DAVID. [Database for Annotation, visualization, and Integrated Discovery]37 Pathway analysis was performed 
to functionally annotate gene groups using standard criteria and an EASE of 0.1. Interferome database38 was used 
to identify an IFN signature in the gene selections, using standard criteria with absolute fold change of ≥ 2 and 
limited to the haematopoietic system38.
Statistical analysis. Statistical analysis was performed using Prism 5.00 (Graphpad, USA). A two-sided stu-
dent’s t-test was used throughout the paper to determine the significance of enhancement after antibody-mediated 
infection. The antiviral response was analysed using One-way ANOVA with Bonferroni compensation. A p-value 
of ≤ 0.05 was considered significant for both tests.
Results
Human monoclonal antibodies enhance dengue virus infection of primary human 
macrophages. Primary macrophages are considered important players in ADE of DENV infec-
tion12,39, yet most of the mechanistic studies conducted so far have been conducted in cell lines26,27,40. 
Although working with primary cells is more challenging than cell lines given the inherent varia-
bility between blood donors and the less pronounced ADE effects in primary cells, we feel that it is 
important to dissect the fundaments of ADE in cells that are thought to contribute to ADE during 
natural infection. Primary human macrophages were generated by culturing isolated blood mono-
cytes for 6 days in the presence of 100 ng/mL M-CSF. The resulting cells showed a typical macrophage 
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expression pattern (Fig. A1). In line with previous literature31,41, primary human macrophages were 
susceptible to DENV2 infection in an MOI-dependent manner (between MOI 0.2 and MOI 10) 
(Fig. A2, and Table 1).
To test for ADE, we used human monoclonal antibodies against distinct epitopes of the DENV envelope 
protein; e.g. domains (D) I/DII (#753 C6), and the DII fusion loop (#751 A2). These antibodies were previously 
shown to be cross-reactive against all four serotypes of DENV42. Notably, we found that the power of enhance-
ment was similar between the antibodies (Fig. 1) and independent of the MOI (Fig. A2). Given the overlapping 
results between the antibodies, we decided to focus on the E DII fusion loop antibody #751 A2 for the remaining 
experiments. Peak enhancement was observed at an antibody concentration of 40 ng/mL, giving 6.8 ± 1.3-fold 
enhancement (N = 9) at MOI 1 (Fig. 1). The observed power of enhancement is comparable to other studies using 
primary human cells23–25.
In line with the current hypothesis of ADE, ADE enhanced both the infected cell mass and the burst size 
(Table 1). The percentage of infection was scored at 26 h post infection (hpi) by flow cytometry. The burst size was 
calculated by dividing the virus titer as measured with plaque assay by the number of infected cells. In absence 
of antibodies, 2.0% ± 0.5 of the cells were infected with DENV at MOI 1. Under conditions of MOI 1-ADE, the 
fraction of infected cells increased to 3.7% ± 0.9 (Table 1). For individual donors, the average enhancement was 
2.3 ± 0.6-fold (MOI 1 versus MOI 1-ADE, p = 0.023, N = 4 donors). At the same time, the burst size increased 
4.2 ± 0.4-fold (N = 4, p = 0.005). The increase in burst size indeed suggests that intrinsic ADE mechanisms are 
involved. Interestingly though, infection at MOI 10 in the absence of antibodies also increased the burst size 
(Table 1). Increased burst sizes were already observed at MOI 2½, and infection at MOI 5 closely mimicked MOI 
1-ADE in terms of burst size and infected cell mass (Table A1).
To determine whether ADE influenced the specific infectivity of the progeny virus (particles per PFU), we 
quantified the number of genome-containing particles (qRT-PCR) and the number of infectious particles (plaque 
assay). In contrast to results from cell lines26, we found that neither antibodies nor MOI influenced the particle/
MOI Infected cells (%) Burst size (PFU/cell) Particles/PFU
1 2.0 ± 0.5 2.8 ± 1.0 255 ± 34
1-ADE 3.7 ± 0.9 8.9 ± 2.4 212 ± 19
10 11.3 ± 2.3 17.2 ± 4.7 268 ± 24
Table 1. Antibodies enhance both infection and burst size, but not the specific infectivity of progeny 
virions. Primary human macrophages were infected at MOI 1 or 10, and MOI 1-ADE. For MOI 1-ADE DENV 
was pre-incubated for 1 h with 40 ng/mL of antibody #751 A2. The number of infected cells was determined by 
flow cytometry at 26 hpi. Concurrently, the virus titer was determined by both qRT-PCR (physical particles) 
and plaque assay (infectious particles). The burst size was calculated by dividing the virus titer by the number 
of infected cells and the specific infectivity resembles the number of physical particles divided by the number of 
infectious particles. All values are SEM of duplicates of 4 donors.
Figure 1. Antibody-dependent enhancement of DENV2 infection of primary human macrophages is dose-
dependent. Macrophages were incubated with DENV2, strain 16681 at MOI 1 which had been pre-incubated 
for 1 h with increasing concentrations of monoclonal human antibody (#753 C6; light grey, or #751 A2; dark 
grey). At 48 hpi, virus production was determined by plaque assay on BHK-15 cells. Shown is the SEM of 
duplicates. The figure is representative for two independent experiments. These antibodies are described more 
in-depth in a previous publication42.
www.nature.com/scientificreports/
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PFU ratio of DENV2 in primary human macrophages (Table 1). This suggests that the observed ADE effect 
occurs prior to assembly, maturation and secretion of progeny virions.
Enhanced transcription and translation during ADE, yet the replication efficiency is unaf-
fected. We next studied the effect of antibodies on protein translation and viral genome replication using flow 
cytometry and qRT-PCR, respectively. Protein translation was determined on a per-cell-basis by measuring the 
mean fluorescence intensity (MFI) of the envelope proteins within the cell. Figure 2 shows that the MFI is clearly 
enhanced under conditions of ADE at 24 hpi (N = 11, p ≤ 0.0001), suggesting that ADE may enhance viral protein 
translation. Higher concentrations of virus (MOI 2½ , MOI 5, and MOI 10), in line with the increased burst size, 
also resulted in higher E protein content per cell yet protein translation did not differ among the higher MOI’s 
(Fig. 2).
Next, the replication efficiency of the virus was determined at 24 hpi by measuring the intracellular ratio of 
positive-sense and negative-sense RNA. ADE leads to 10-fold higher numbers of both negative- (9.8 ± 4.4, N = 3) 
and positive-sense (9.8 ± 3.5, N = 4) RNA. Yet, the ratio of positive versus negative RNA was comparable between 
MOI 1 and MOI 1-ADE (4.9 ± 1.0 versus 4.8 ± 2.7, respectively (N = 4)), suggesting that antibody-mediated 
infection does not influence the replication efficiency of DENV. Contrary to this, infection at MOI 5 showed a 
ratio of 2.5 ± 1.5 (N = 4), indicating that the replication efficiency is negatively affected under conditions of higher 
MOI’s.
Thus, the increased burst size during ADE is associated with enhanced transcription and translation while the 
replication efficiency is similar to MOI 1. In absence of antibodies, similar infectivity, burst size and translation 
can be attained using higher MOIs yet at the cost of the replication efficiency.
Antibodies enhance fusion while maintaining the same cellular dose of virus particles. It is 
assumed that the higher number of genome copies and increased protein translation is a consequence of higher 
virus cell binding and/or increased uptake of particles into cells. Therefore, we quantified virus binding and cell 
entry using qRT-PCR. To measure viral entry, extracellular virions were removed by washing the cells with a 
high-salt-high-pH buffer43.
Overall, virus cell binding (squares) and entry (circles) was not enhanced under conditions of ADE (N = 4 
donors) (Fig. 3A). We were surprised by these findings, yet we were not able to use qRT-PCR at later time points 
due to the initiation of replication as visualized by the negative sense RNA (triangles, Fig. 3A). Therefore, we next 
used flow cytometry to assess the binding and entry dynamics of DENV2 in individual cells using PKH67-labelled 
DENV particles. PKH67 is a fusion-independent lipophilic dye that intercalates into the viral membranes36. 
This approach allows us to measure viral uptake and reveals the population of cells that are positive for PKH67. 
DENV2 was successfully labelled with PKH67 (Fig. A3).
Figure 3B shows the extent of DENV2 uptake against the cell population positive for uptake at 1 hpi (filled 
shape) and 2 hpi (striped shape). The extent of virus uptake per cell as well as the fraction of positive cells 
increased over time. Comparable results were obtained for MOI 1 (blue) and MOI 1-ADE (red). Yet, at MOI 5 
(green) both the fraction of PKH67-positive cells and the extent of viral uptake per cell were higher than MOI 
1/1-ADE at both time points (Fig. 3B). These results are in line with the qRT-PCR data (Fig. 3A), and confirm that 
ADE does not enhance the binding- or entry-efficiency of DENV2 in primary macrophages.
Hence, we hypothesized that antibodies enhance a step downstream of entry and prior to replication. For 
example, antibodies may direct the virus to an organelle and/or cellular location that is more beneficial for mem-
brane fusion and infection. Alternatively, antibodies may enhance the intrinsic fusion capacity of the virus. To 
Figure 2. Antibodies and infection at high MOI enhance virus translation. Viral translation was determined 
per cell on the intracellular pool of envelope protein. Macrophages were infected with DENV2. At 24–26 h, 
cells were stained with the anti-envelope antibody 4G2 and analysed by flow cytometry. Mean fluorescence 
intensities were normalized to the sample with the highest intensity of the donor. Up to 11 blood donors were 
used and six donors were used twice. Statistical analysis was done by One way ANOVA with Bonferroni post-
test correction; * (p ≤ 0.05), * * (p ≤ 0.01) * * * (p ≤ 0.0001), n.s.: non-significant.
www.nature.com/scientificreports/
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assess if antibody-mediated DENV entry increases the fusion potential of the virus, we employed a microscopic 
fusion assay involving DiD-labelled DENV. Fusion is observed as a sudden increase in fluorescence intensity due 
to dilution of the probe in the target membrane34,35,44. Figure 3C shows that this assay is specific and robust since 
the extent of fusion was MOI-dependent and inhibited by ammonium chloride (Fig. 3C, ref. 34). Importantly, 
membrane fusion activity of DENV under conditions of ADE was enhanced with 65% (Fig. 4A). Furthermore, 
the number of fusion-positive macrophages increased with 40% (Fig. 3D). The extent to which fusion is enhanced 
is variable between donors and ranged from 115% to 336% (Fig. 3E inset). Importantly, when the extent of fusion 
enhancement is plotted against those for the PFU production, the results are correlating with each other, indicat-
ing a causal relationship between the two parameters (Fig. 3E).
Recently, we performed similar experiments in the macrophage-like cell line P338D1 (Ayala et al., accompa-
nying manuscript). In contrast to our results for primary human macrophages, we did find enhanced binding/
entry of DENV in P338D1 cells under conditions of ADE and subsequent higher fusion activity (3.85 ± 0.5 and 
3.52 ± 0.64 fold change, respectively). This suggests that the qRT-PCR is able to detect differences in binding and 
entry where they occur, but also that the mechanism of ADE is cell-type-specific.
We next attempted to assess if antibodies itself influence the fusion potential of the virus using a cell-free lipo-
somal system. However, despite our experience in virus-liposome fusion studies45–47, we were not able to detect 
fusion of DENV with negatively-charged liposomes (data not shown). Thus we were not able to examine whether 
antibodies intrinsically promote membrane fusion of DENV.
Figure 3. Antibodies do not alter the efficiency of dengue virus to bind or enter into primary human 
macrophages, whilst promoting fusion within primary macrophages. (A) DENV2 binding and uptake in 
primary macrophages was determined at 1 hpi by qRT-PCR using template-specific primers in combination 
with RNAse A treatment. Extracellular virus was removed by shaving the cells with a high-salt-high-pH buffer 
for 2 min. Squares show the total number of virus particles that had bound or entered cells. Circles depict 
entered viral genomes, while triangles show negative-sense RNA genomes. Shown are 4 donors with each 
condition in duplicate. (B) Macrophages were infected with PKH67-labelled DENV at MOI 1 (red), MOI 
1-ADE (blue) or MOI 5 (green). At 1 h (filled) or 2 h (striped) of incubation, the cells were shaved and fixed 
prior to analysis by flow cytometry. Cell entry was normalized to MOI 1, and the mean fluorescence intensity 
(MFI) was normalized to the negative control. Shown are the SEM of 5 donors. At MOI 1, 13 ± 3% of the cells 
were positive for PKH67-labelled DENV entry. (B–E) The fusion activity of DENV2 within primary human 
macrophages was determined at 30 min by microscopy using the self-quenching fluorophore DiD. Pictures  
were taken randomly and analysed for fusion activity (C), and the fraction of fusion-positive cells (D). All 
values were normalized to MOI 1 of the same donor (C) or infection in absence of antibodies (D,E). At MOI 
1, the average number of fusion-positive cells was 17 ± 2.2%. (E) An overview of connected values of fusion 
activity when primary human macrophages are infected in the presence of enhancing antibodies (ADE), and 
when infected in the presence of an isotype (IgG). The inset shows the correlation between enhancement of 
fusion activity at 30 min post infection and the subsequent enhancement in virus production at 26 hpi. All 
values are given as percentage of the results obtained at MOI 1. Shown are the normalized SEM of up to 12 
donors (A–C) and 5 experiments (D,E). Statistical analysis was done by 2-tailed t-test; * (P ≤ 0.05), * * (P ≤ 0.01), 
* * * (P ≤ 0.0005).
www.nature.com/scientificreports/
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To summarize, ADE in both models led to more fusion-positive cells and more fusion activity per cell (i.e. 
higher genome delivery). The relatively small increase in fusion activity probably initiates a cascade leading to 
higher infection rates and burst sizes. In primary human macrophages, the efficiency of infection and the burst 
size is however not solely dependent on membrane fusion activity since MOI 5 and ADE had a similar infected 
cell mass and burst size, while at MOI 5 a five-fold higher fusion activity was seen compared to ADE. This sug-
gests that the infection process is negatively influenced at MOI 5 compared to MOI 1-ADE. Therefore, we next 
wished to better understand what happens within the cell to-be-infected.
Gene profiles of DENV-infected macrophages discriminate between high and low infection. 
To identify the cellular responses during DENV infection, we profiled the gene expression patterns at 2 and 
24 hpi. Macrophages were infected at MOI 1, and MOI 1-ADE to study the biological process of ADE. Also, 
infection-matched controls, with a similar fraction of infected cells (MOI 2½ or MOI 5, depending on the donor), 
were included to better understand the increased burst size observed at high MOI. As controls, we included 
non-infected cells and infections at MOI 1 in the presence of non-relevant antibodies (1-IgG). All donors and 
conditions were normalized to the mock, and genes with a fold-change of ≥ 1.5 of the mock were selected. Venn 
diagrams were drawn to visualize the overlaps between various conditions of infection.
First, we studied the biological process of ADE at 24 hpi.The Venn diagram for this time point shows that ADE 
induces a strong alteration in the transcriptional profile of infected human macrophages; 101 genes were shared 
between MOI 1 and MOI 1-ADE, while 460 genes were uniquely for ADE. Contrary to this, only 2 genes were 
unique to infection at MOI 1 without antibodies.
Yet, a comparison of MOI 1-ADE with the infection-matched control shows that a large majority of the 
ADE-genes are associated with high infection (319 genes, Fig. 4A). Thus, the transcriptional response upon ADE 
is likely induced by the larger infected cell mass and/or higher viral load in the supernatant (2-fold and 8-fold 
higher than MOI 1, respectively). DAVID pathway analysis37 was used to functionally annotate the gene patterns 
(Fig. 5B,C). We were interested in two sets of genes: the shared genes (100 genes, Fig. 4A) and the ADE-associated 
genes (141 + 319 genes, Fig. 4A). Gene ontology identified the term “antiviral defense” as the most significant 
term for the shared genes (Fig. 4B). For the ADE-associated genes, the sole significant term was “inflammatory 
responses” (Fig. 4C), hence antibodies did not induce a long-lasting immune-suppressive state in our macrophage 
cultures.
Figure 4. Dengue virus infection of macrophages induces an antiviral response, which depends on the viral 
load. (A,D) Primary human macrophages were infected with DENV2 at MOI 1, MOI 1-ADE, and matched 
infection (MOI 5 or MOI 2½). Total RNA was isolated at 24 h (A) and 2 h (D). Gene expression was investigated 
by microarray. Genes whose average expression had an absolute fold change of at least 1.5-fold over the mock 
were selected. The Venn diagram shows how these genes are connected with the various infection conditions. 
(A) is based on 3 donors and (D) on 4 donors. (B,C,E) Gene ontology of DAVID pathway analysis was used to 
annotated genes at 24 h (B,C) and at 2 h (E). (B) shows the ontological analysis of the genes that were shared 
among the three conditions (see A, triangle, 100 genes).(C) shows the analysis of the ADE-effect (see A, 460 
genes total; 318 + 142). (E) shows the ontological analysis of the genes that were shared among the three 
conditions at 2 h (see D, triangle, 160 genes). The x-axis shows the enrichment of the term within our selection 
relative to the DAVID database. The y-axis shows the significance calculated with 1-tailed Fisher Exact statistical 
analysis. Gene ontology terms with at least 5-fold enrichment and a p-value of ≤ 1 ∙ 10−4 are considered relevant.
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Hence, we focused on the transcriptional profiles shortly after infection. At 2 hpi, both MOI 1 and MOI 1-ADE 
had very similar transcriptional profiles (Fig. 4D). Contrary to this, MOI 5 showed a much stronger shift in 
its transcriptional profile. The lack of difference between MOI 1 and MOI 1-ADE at 2 hpi is in contrast with 
the 24 hpi time point (Fig. 4A,D, respectively), suggesting that antibodies do not induce specific transcriptional 
profiles. A comparison of the profiles induced by MOI 1, MOI 1-IgG and MOI 1-ADE indeed revealed that 
infection in the presence of DENV antibodies does not induce specific pathways (Fig. A4). At 2 hpi, 160 of the 
genes were shared between the three conditions (triangle, Fig. 4D). Gene ontology analysis of these 160 shared 
genes identified an inflammatory response (Fig. 4E). No specific suppressive pathway was identified in the MOI 
1-ADE cluster (Fig. 4E). Thus, at both time points of infection, antibody-mediated infection did not activate 
immune-suppressive pathways. Rather, we found high induction of the cytokines IFNβ , TNFα , IL1β , IL6 and little 
to no IL10 (Fig. A4B). Moreover, the fraction of interferon (IFN)-regulated genes38 is quite substantial (Table 2), 
suggesting that there was an antiviral state in our cultures despite the antibody-dependent infection mechanism.
Figure 5. Early type-I-interferon (IFN)-mediated responses significantly determine the outcome of 
infection. (A) Primary macrophages were infected with DENV2 at MOI 1, MOI 1-ADE, MOI 5, and MOI 
10. Culture supernatants were harvested at 24 h and UV-inactivated. Inactivated supernatants were used to 
pre-activate Vero cells prior to infection with VSV at MOI 0.1. Shown is the SEM of 3 donors, with infection 
performed in duplicate and duplicates of this assay. Statistical analysis was done with One way ANOVA with 
post-test Bonferroni compensation; * * (p ≤ 0.01) and n.s.; non-significant. (B) IFNα protects primary human 
macrophages against DENV2 infection when applied during the early (0–2 hpi) time points, and not during 
late (8 hpi) time points. Macrophages were infected with DENV2 at MOI 1, MOI 1-ADE and MOI 5. At the 
designated time points, 1 IU of recombinant human IFNα 2a was added to the culture. At 26 hpi, the viral titre 
in the supernatant was determined by qRT-PCR and normalized relative to the unperturbed condition (No 
IFNα ). Shown is the SEM of 4–5 donors, each condition in duplicate. (C) Type I IFN signalling was blocked by 
pre-incubating macrophages for 2 h with an antibody against the IFNα β R. After incubation, cells were infected 
at MOI 1, MOI 1-ADE and MOI 5. Supernatants were sampled at 26 hpi and virus production was determined 
by qRT-PCR. Addition of 10 units of IFNα at 0 hpi served as a control for IFNα β R-blocking. Shown is the 
normalized SEM of 2 donors, each condition in duplicate.
Shared MOI 5 unique Shared MOI 5 & 1-ADE
2 hpi 30.9% (160 genes) 25.7% (152 genes) xxx
24 hpi 79.8% (100 genes) xxx 49.2% (319 genes)
Table 2. High viral load stimulates IFN-regulated genes early in infection. Genes were selected from 
the Venn diagrams in Fig. 4A (24 h) and 4E (2 h). Selected genes were analysed by mining the Interferome 
database38 for interferon-regulated genes in haematopoietic cells which are reported as the percentage of the 
selected genes.
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Antibodies enhance fusion while avoiding additional antiviral responses. Microarrays provide a 
snap-shot of the expression profile at the mRNA level. To confirm the antiviral state, we next analysed the antivi-
ral activity of the macrophage supernatants described above (Fig. 5A). As different cytokine profiles can confer 
the same protection48, we used a viral bio-assay25 combining the IFN-sensitive VSV49 with the IFN-deficient yet 
-sensitive Vero WHO cell line50. At 24 hpi, no antiviral activity towards VSV was observed in the supernatants of 
macrophages infected at MOI 1 of DENV without antibodies. Yet, following infection at MOI 1-ADE, MOI 5 and 
MOI 10, antiviral activity was seen (Fig. 5A). This indicates that antibodies per se do not induce a virus-tolerant 
environment by 24 hpi. Moreover, antiviral responses appear to increase with the percentage of DENV2-infected 
macrophages (Fig. 5A, Table 1 and A1), indicating a dose-dependent response.
At 24 hpi, MOI 5 had a comparable number of infected cells, antiviral activity and burst size as MOI 1-ADE. 
Yet, MOI 5 had a 5-fold higher fusion activity and a 2-fold lower replication efficiency. Moreover, more genes 
are potentially IFN-regulated (Table 2). Earlier studies in human cell lines showed that the sensitivity of DENV 
to IFN is most pronounced during early stages of the viral life cycle, and over time the virus becomes resist-
ant to the antiviral activity of IFN43. Hence, we hypothesized that a high MOI of DENV2 induces a stronger, 
type-I-IFN-mediated response early in infection thereby lowering the replication efficiency. To confirm our 
hypothesis, we first attempted to quantify the concentrations of IFNα and IFNβ at 2 hpi in the macrophage super-
natants from the screen by ELISA. The IFNβ concentration was below the limit of detection for all conditions, and 
the IFNα concentration fluctuated between the donors and conditions likely due to the very low concentrations 
measured (Table A2).
To evaluate if DENV also becomes resistant to IFN in primary macrophages, we added exogenous IFN to 
cells at different time points post-infection and assessed virus production. Indeed, and in line with earlier results, 
the antiviral activity of IFNα is most pronounced when added early in infection (Fig. 5B). At late time points, 
the effect of exogenous IFN diminishes indicating that once infection is established the antiviral effect of IFN is 
limited. Importantly, the effect of exogenous IFN was distinct between the conditions tested with the lowest effect 
at MOI 5 and the strongest effect at MOI 1. The higher resistance at MOI 5 is indicative for an endogenous IFN 
response early in infection, since the added IFN had a lower contribution to the antiviral state already present in 
the culture. Interestingly, Fig. 5B also shows that the addition of just one unit of IFNα to the cells at the time of 
infection significantly reduces ADE (4-fold reduction in virus production), indicating that ADE is sensitive to 
IFN.
If, at MOI 5, the early endogenous IFN response reduces virus particle production, then blocking the IFNα βR 
prior to infection should lead to an increase in virus production. Indeed, specific blocking type-I-IFN receptor 
signalling significantly enhanced virus production at MOI 5 (Fig. 5C and A5). Interestingly, and in contrast, 
infection at MOI 1 or MOI 1-ADE was not enhanced by the IFNα β R antibody, confirming that MOI 1 and MOI 
1-ADE do not trigger IFNα β R-signalling during the early stages of infection. This suggests that the efficiency of 
DENV2 infection in primary human macrophages is determined by the balance between fusion activity and anti-
viral responses early in infection. Once DENV infection and replication is established, the antiviral response no 
longer determines virus production (Fig. 5A(+ 24 hpi) and 5B(+ 8 hpi)), likely due to the viral proteins51.
Discussion
Antibody-mediated cell entry of DENV is known to increase the infected cell mass and virus particle production, 
but little is known about the underlying mechanisms. Our results show that, in primary macrophages, antibod-
ies enhance DENV infection by promoting fusion (Fig. 3C,E), while no altered uptake of virus particles is seen 
(Fig. 3A,B). The higher fusion potential triggers a cascade of events leading to enhanced infection, replication, 
translation, and burst size. Furthermore, the presence of enhancing concentrations of antibodies did not trigger 
pro- or anti-viral programs early in infection (Fig. 4E). At high MOI, however, increased binding, uptake, fusion 
and an increased antiviral response is seen early in infection (Figs 3A–D and 5C).
Our results show that fusion is the first step within primary macrophages where antibodies have a positive 
influence on the life cycle of DENV. Indeed, not only the total extent of virus cell binding but also the over-
all distribution of virus particles among cells was comparable in the absence and in the presence of antibodies 
(Fig. 3A,B). The increase in membrane fusion activity does, however, not directly translate into the observed 
increase in the burst size. Yet, it is interesting to note that the extent of membrane fusion activity correlates with 
virus production (Fig. 3E inset). This is suggestive for a causal relationship between fusion activity and virus pro-
duction in primary macrophages. Further research is required to investigate the downstream effects of ADE more 
in-depth. Important steps to elucidate herein are for example the effect on nucleocapsid delivery, nucleocapsid 
uncoating and subsequent initiation of protein translation.
We propose that the “normal” binding and entry characteristics of ADE is key to the success of ADE in pri-
mary macrophages as this avoids extensive activation of antiviral signalling early in infection (Fig. 5B). Indeed, 
blocking IFNα β R-signalling rescued DENV production at MOI 5 but had no effect at MOI 1 or 1-ADE (Fig. 5C). 
Contrary to MOI 5, ADE displays enhanced fusion activity while maintaining low antiviral responses (Fig. 5C). 
Collectively, our results suggest that ADE of DENV infection in primary macrophages involves a novel mech-
anism that is tightly balanced between the extents of binding, entry, fusion and the antiviral responses early in 
infection (Fig. 6).
In contrast to our results in primary macrophages, we did observe enhanced binding of DENV- 
immune-complexes in macrophage-like P338D1 cells (Ayala et al., accompanying manuscript). In P338D1 cells, 
we noted 3.85-fold higher binding/uptake of DENV into the cells and 3.52-fold higher fusion activity, which sug-
gests that ADE in P338D1 cells is facilitated by an increased binding efficiency of the virus-immune-complexes to 
the cell. These results suggests that alternative, cell-type-specific, mechanisms exists to facilitate ADE. An alter-
native explanation for our findings in primary macrophages is that virus particles are non-randomly distributed 
and cells that support ADE are more permissive than other cells. While this notion deserves further research, it 
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seems unlikely as the overall distribution of virus particles was comparable in the presence and in the absence of 
antibodies (Fig. 3B).
ADE could be mimicked in terms of infected cell mass and burst size by infection at high MOI. Furthermore, 
strong overlapping transcriptional profiles and antiviral responses were observed late in infection. This sug-
gests that antibodies do not trigger specific intrinsic pathways. Indeed, no antibody-specific anti-inflammatory 
program was found in primary human macrophages (Fig. 5D and A4). This in agreement with a recent whole 
blood transcriptome analysis52 and in contrast with studies using PBMCs19 or cell lines53. Furthermore, other 
studies described a “muted” response54,55, but argued that the actual response could have waned by the time 
of sampling54,56. Therefore, the antibody-dependent immune suppression could be specific for the cell type(s) 
investigated.
In monocytes, the anti-inflammatory cytokine IL10 is considered to be one of the driving forces of intrinsic 
ADE29,53. In macrophages, however, we and others found low induction of IL10 after ADE (Fig. 5F, refs 25,57), 
and only at late time points for conditions with high infection and viral load (Fig. 5F, ref. 58). Hence, IL10 does 
not directly influence ADE of DENV infection in macrophages. In line with this, IL10-primed macrophages 
are highly susceptible to DENV infection but do not produce progeny virus59. This manuscript focused only on 
primary human macrophages and future research will have to elucidate the role of IL10 in DENV-ADE in other 
cell types. Based on our results, we propose that the enhanced burst size, as observed in human macrophages, is 
dependent on the effective MOI (fusion extent) and is not antibody-specific.
Dengue haemorrhagic fever is characterized by vascular leakage, which on its turn has been linked to the high 
inflammatory response in patients (reviewed in: ref. 60) and the action of the DENV NS161,62. Here we show that 
antibody-dependent DENV infection of primary human macrophages results in 7-fold higher virus titres, and 
subsequently triggers strong inflammatory responses (Figs 5C,F and 6A,25). The link between viral burden and 
vascular permeability has been described before24,52,61,62 and our data further strengthens the notion that dengue 
haemorrhagic fever might be alleviated by reducing the viral load. Indeed, we show that application of IFNα 
suppressed virus production by human macrophages, even under conditions of ADE.
An important remaining question is how the antibodies enhanced the fusion efficiency of the internal-
ized particles. There are two options; (i) antibodies directly enhance the fusion potential of the virus, or 
(ii) the phagosomal environment of primary macrophages is more favourable for fusion. Although we can-
not disprove the first hypothesis, it seems unlikely as no epitope-specific effects were seen in ADE (data not 
shown). Antibody-mediated cell entry is facilitated through interaction of the antibody with the Fc receptor. 
Due to this interaction, DENV-immune-complexes are internalized via phagocytosis (Ayala et al., accompanying 
manuscript). DENV fusion is critically dependent on pH and negatively charged lipids34,63. These factors are 
Figure 6. Molecular mechanisms involved in antibody-dependent enhancement of dengue virus 
infection in primary human macrophages. Antibody-dependent infection does not enhance binding or 
entry of the virus to the cells. Yet, the membrane fusion potential within the endosomes of the macrophage 
is increased. Thanks to the unaltered characteristics of binding and entry, ADE does not trigger endogenous 
interferon-responses which thus allows the virus to replicate freely during the early stages of infection. ADE 
can be mimicked in terms of the number of infected cells and burst size by infection at high MOI in absence 
of antibodies. Yet high MOI leads to more binding, entry, fusion, and as a consequence induction of an IFN 
response. The presence of an early IFN response significantly reduces virus replication and production. ADE 
is thus based on higher fusion but due to the absence of an early IFN response, it remains unnoticed by the cell 
allowing virus replication to higher titres.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:29201 | DOI: 10.1038/srep29201
differentially regulated and distributed between distinct organelles63,64, and may explain why enhanced fusion is 
seen in primary macrophages.
In conclusion; antibodies enhance DENV infection of human macrophages by promoting fusion of the virus 
particles within endosomes. Our work suggests that the higher effective MOI (fusion, translation, replication) 
causes the enhanced burst size, not the interaction of antibodies with the FcR. We show that even modest enhance-
ment of fusion activity initiates a cascade with increasingly aggravating impacts. Importantly, DENV2-ADE does 
not suppress antiviral responses, but rather avoids induction hereof. We show that DENV2-ADE can be sig-
nificantly suppressed by addition of IFNα to primary human macrophages. These IFN-experiments and our 
microarray show that the dreaded induction of immunosuppression apparently is not involved in DENV-ADE in 
macrophages. Therefore, the presented work offers new perspectives to treat dengue virus, with fusion and antivi-
ral responses as the key steps between high and low infection in primary human macrophages.
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